Achla Gupta
Overview
Explore the profile of Achla Gupta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
1466
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gomes I, Gupta A, Margolis E, Fricker L, Devi L
Mol Pharmacol
. 2024 Aug;
106(5):240-252.
PMID: 39187388
Ketamine is a glutamate receptor antagonist that was developed over 50 years ago as an anesthetic agent. At subanesthetic doses, ketamine and some metabolites are analgesics and fast-acting antidepressants, presumably...
2.
Gupta A, Gomes I, Osman A, Fujita W, Devi L
J Pharmacol Exp Ther
. 2024 Aug;
391(2):279-288.
PMID: 39103231
Cannabinoid and opioid receptor activities can be modulated by a variety of post-translational mechanisms including the formation of interacting complexes. This study examines the involvement of endogenous and exogenous chaperones...
3.
Dong C, Gowrishankar R, Jin Y, He X, Gupta A, Wang H, et al.
Nat Neurosci
. 2024 Jul;
27(9):1844-1857.
PMID: 39009835
Neuropeptides are ubiquitous in the nervous system. Research into neuropeptides has been limited by a lack of experimental tools that allow for the precise dissection of their complex and diverse...
4.
Duarte M, Wang M, Gomes I, Liu C, Sharma A, Fakira A, et al.
Mol Pharmacol
. 2023 May;
104(1):1-16.
PMID: 37147110
Current treatments for Alzheimer's disease (AD) help reduce symptoms for a limited time but do not treat the underlying pathology. To identify potential therapeutic targets for AD, an integrative network...
5.
Mack S, Gomes I, Fakira A, Duarte M, Gupta A, Fricker L, et al.
Mol Pharmacol
. 2022 May;
102(1).
PMID: 35605991
PEN is an abundant neuropeptide that activates GPR83, a G protein-coupled receptor that is considered a novel therapeutic target due to its roles in regulation of feeding, reward, and anxiety-related...
6.
Toniolo E, Gupta A, Franciosi A, Gomes I, Devi L, Dale C
Pain
. 2021 Nov;
163(7):1414-1423.
PMID: 34724682
Diabetic neuropathy, often associated with diabetes mellitus, is a painful condition with no known effective treatment except glycemic control. Studies with neuropathic pain models report alterations in cannabinoid and opioid...
7.
Kunselman J, Gupta A, Gomes I, Devi L, Puthenveedu M
Elife
. 2021 Apr;
10.
PMID: 33908346
Many signal transduction systems have an apparent redundancy built into them, where multiple physiological agonists activate the same receptors. Whether this is true redundancy, or whether this provides an as-yet...
8.
Duarte M, Trimbake N, Gupta A, Tumanut C, Fan X, Woods C, et al.
Commun Biol
. 2021 Feb;
4(1):238.
PMID: 33619305
Antibodies represent powerful tools to examine signal transduction pathways. Here, we present a strategy integrating multiple state-of-the-art methods to produce, validate, and utilize antibodies. Focusing on understudied synaptic proteins, we...
9.
Gupta A, Gullapalli S, Pan H, Ramos-Ortolaza D, Hayward M, Low M, et al.
Cell Mol Neurobiol
. 2021 Jan;
41(5):1103-1118.
PMID: 33389463
Activation of μ, δ, and κ opioid receptors by endogenous opioid peptides leads to the regulation of many emotional and physiological responses. The three major endogenous opioid peptides, β-endorphin, enkephalins,...
10.
Faouzi A, Uprety R, Gomes I, Massaly N, Keresztes A, Le Rouzic V, et al.
J Med Chem
. 2020 Nov;
63(22):13618-13637.
PMID: 33170687
In this work, we studied a series of carfentanyl amide-based opioid derivatives targeting the mu opioid receptor (μOR) and the delta opioid receptor (δOR) heteromer as a credible novel target...